Tag: M.W=300-400

Electric Literature of C6H12N2O4Pt. The protonation of heteroatoms in aromatic heterocycles can be divided into two categories: lone pairs of electrons are in the aromatic ring conjugated system; and lone pairs of electrons do not participate. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Non-small Cell Lung Cancer.. Author is Horiuchi, Minoru; Oguri, Tetsuya; Kagawa, Yusuke; Sone, Kazuki; Fukuda, Satoshi; Uemura, Takehiro; Takakuwa, Osamu; Maeno, Ken; Fukumitsu, Kennsuke; Kanemitsu, Yoshihiro; Tajiri, Tomoko; Ohkubo, Hirotsugu; Takemura, Masaya; Ito, Yutaka; Niimi, Akio.

BACKGROUND/AIM: The optimal chemotherapy for concurrent chemoradiotherapy (cCRT) of lung cancer is still unclear. PATIENTS AND METHODS: We investigated the therapeutic effect of different chemotherapy regimens for cCRT of lung cancer in 65 patients at our hospital. RESULTS: Of the 65 patients, 53 were male and 12 female. The median age was 64 years and 58 participants had a smoking history. The histological type was adenocarcinoma in 34 cases, squamous cell carcinoma in 22 cases, and others in 9 cases. Induction therapy consisted of cisplatin plus vinorelbine (CDDP+VNR) in 50 cases, and weekly carboplatin plus paclitaxel (CBDCA+PTX) in 15 cases. In all patients, the overall response rate, disease control rate, median progression survival, and median overall survival were 78.5%, 95.4%, 337 days, and 1,037 days, respectively. The median progression-free survival was 337 days in total; it was significantly longer for CDDP+VNR than CBDCA+PTX. The median overall survival was 1,037 days in total; it tended to be slightly longer for CDDP+VNR than CBDCA+PTX. CONCLUSION: Different chemotherapy regimens for cCRT possibly have different therapeutic effects.

Here is just a brief introduction to this compound(41575-94-4)Electric Literature of C6H12N2O4Pt, more information about the compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)) is in the article, you can click the link below.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Related Products of 41575-94-4. The protonation of heteroatoms in aromatic heterocycles can be divided into two categories: lone pairs of electrons are in the aromatic ring conjugated system; and lone pairs of electrons do not participate. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. Author is Vidra, Radu; Nemes, Adina; Vidrean, Andreea; Pintea, Sebastian; Tintari, Snejeana; Deac, Andrada; Ciuleanu, Tudor.

Meta-anal. of the addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-neg. breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast cancer, particularly in the TNBC subgroup. In order to assess the efficacy of each most representative platinum agent (cisplatin and carboplatin) in patients with TNBC treated with NACT, the present study performed a systematic review and meta-anal. of all available published studies on TNBC. A search of PubMed was performed to identify studies that investigated platinum-based NACT in patients with TNBC. The primary endpoints were the pooled rate of the pathol. complete response (pCR) between cisplatin vs. carboplatin-based NACT. A total of 24 studies were selected (17 studies for carboplatin and 6 studies for cisplatin and 1 study with both carboplatin and cisplatin, with 20 prospective studies) for the anal. of 1,711 patients with TNBC. Overall, the pooled rate of pCR in patients treated with platinum-based NACT was 48%. No significant differences were observed between the rates of pCR obtained under carboplatin vs cisplatin treatment. The carboplatin pCR rate was 0.470 [95% confidence interval (CI), 0.401-0.539], while the cisplatin pCR rate was 0.473 (95% CI, 0.379-0.568). The comparison between these two categories revealed no significant differences (P=0.959). In the whole, the present study demonstrates that neoadjuvant platinum-based chemotherapy improves the pCR rate in patients with TNBC, regardless of the platinum agent used. Carboplatin may thus represent a viable option due to its more favorable toxicity profile.

Here is just a brief introduction to this compound(41575-94-4)Related Products of 41575-94-4, more information about the compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)) is in the article, you can click the link below.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Category: esters-buliding-blocks. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. Author is Roy, Sudipta; Whitehead, Timothy D.; Li, Shunqiang; Ademuyiwa, Foluso O.; Wahl, Richard L.; Dehdashti, Farrokh; Shoghi, Kooresh I..

We sought to exploit the heterogeneity afforded by patient-derived tumor xenografts (PDX) to first, optimize and identify robust radiomic features to predict response to therapy in subtype-matched triple neg. breast cancer (TNBC) PDX, and second, to implement PDX-optimized image features in a TNBC co-clin. study to predict response to therapy using machine learning (ML) algorithms. TNBC patients and subtype-matched PDX were recruited into a co-clin. FDG-PET imaging trial to predict response to therapy. One hundred thirty-one imaging features were extracted from PDX and human-segmented tumors. Robust image features were identified based on reproducibility, cross-correlation, and volume independence. A rank importance of predictors using ReliefF was used to identify predictive radiomic features in the preclin. PDX trial in conjunction with ML algorithms: classification and regression tree (CART), Naive Bayes (NB), and support vector machines (SVM). The top four PDX-optimized image features, defined as radiomic signatures (RadSig), from each task were then used to predict or assess response to therapy. Performance of RadSig in predicting/assessing response was compared to SUVmean, SUVmax, and lean body mass-normalized SULpeak measures. Sixty-four out of 131 preclin. imaging features were identified as robust. NB-RadSig performed highest in predicting and assessing response to therapy in the preclin. PDX trial. In the clin. study, the performance of SVM-RadSig and NB-RadSig to predict and assess response was practically identical and superior to SUVmean, SUVmax, and SULpeak measures. We optimized robust FDG-PET radiomic signatures (RadSig) to predict and assess response to therapy in the context of a co-clin. imaging trial.

I hope my short article helps more people learn about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Category: esters-buliding-blocks. Apart from the compound(41575-94-4), you can read my other articles to know other related compounds.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot》. Authors are Lasiter, Laura; Tymejczyk, Olga; Garrett-Mayer, Elizabeth; Baxi, Shrujal; Belli, Andrew J.; Boyd, Marley; Christian, Jennifer B.; Cohen, Aaron B.; Espirito, Janet L.; Hansen, Eric; Sweetnam, Connor; Robert, Nicholas J.; Small, Mackenzie; Stewart, Mark D.; Izano, Monika A.; Wagner, Joseph; Natanzon, Yanina; Rivera, Donna R.; Allen, Jeff.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). Through the article, more information about this compound (cas:41575-94-4) is conveyed.

In prior work, Friends of Cancer Research convened multiple data partners to establish standardized definitions for oncol. real-world end points derived from electronic health records (EHRs) and claims data. Here, we assessed the performance of real-world overall survival (rwOS) from data sets sourced from EHRs by evaluating the ability of the end point to reflect expected differences from a previous randomized controlled trial across five data sources, after applying inclusion/exclusion criteria. The KEYNOTE-189 clin. trial protocol of platinum doublet chemotherapy (chemotherapy) vs. programmed cell death protein 1 (PD-1) in combination with platinum doublet chemotherapy (PD-1 combination) in first-line nonsquamous metastatic non-small cell lung cancer guided retrospective cohort selection. The Kaplan-Meier product limit estimator was used to calculate 12-mo rwOS with 95% confidence intervals (CIs) in each data source. Cox proportional hazards models estimated hazard ratios (HRs) and associated 95% CIs, controlled for prognostic factors. Once the inclusion/exclusion criteria were applied, the five resulting data sets included 155 to 1,501 patients in the chemotherapy cohort and 36 to 405 patients in the PD-1 combination cohort. Twelve-month rwOS ranged from 45% to 58% in the chemotherapy cohort and 44% to 68% in the PD-1 combination cohort. The adjusted HR for death ranged from 0.80 (95% CI: 0.69, 0.93) to 1.15 (95% CI: 0.71, 1.85), controlling for age, gender, performance status, and smoking status. This study yielded insights regarding data capture, including ability of real-world data to precisely identify patient populations and the impact of criteria on end points. Sensitivity analyses could elucidate data set-specific factors that drive results.

I hope my short article helps more people learn about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). Apart from the compound(41575-94-4), you can read my other articles to know other related compounds.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.》. Authors are Moore, Kathleen N; Chambers, Setsuko K; Hamilton, Erika P; Chen, Lee-May; Oza, Amit M; Ghamande, Sharad A; Konecny, Gottfried E; Plaxe, Steven C; Spitz, Daniel L; Geenen, Jill J J; Troso-Sandoval, Tiffany A; Cragun, Janiel M; Rodrigo Imedio, Esteban; Kumar, Sanjeev; Mugundu, Ganesh M; Lai, Zhongwu; Chmielecki, Juliann; Jones, Suzanne F; Spigel, David R; Cadoo, Karen A.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).SDS of cas: 41575-94-4. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

PURPOSE: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer. PATIENTS AND METHODS: Women with histologically or cytologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer with measurable disease were enrolled between January 2015 and January 2018 in this open-label, four-arm, multicenter, phase II study. Patients received adavosertib (oral capsules, 2 days on/5 days off or 3 days on/4 days off) in six cohorts from 175 mg once daily to 225 mg twice daily combined with gemcitabine, paclitaxel, carboplatin, or pegylated liposomal doxorubicin. The primary outcome measurement was overall response rate. RESULTS: Three percent of patients (3/94) had confirmed complete response and 29% (27/94) had confirmed partial response. The response rate was highest with carboplatin plus weekly adavosertib, at 66.7%, with 100% disease control rate, and median progression-free survival of 12.0 months. The longest median duration of response was in the paclitaxel cohort (12.0 months). The most common grade ≥3 adverse events across all cohorts were neutropenia [45/94 (47.9%) patients], anemia [31/94 (33.0%)], thrombocytopenia [30/94 (31.9%)], and diarrhea and vomiting [10/94 (10.6%) each]. CONCLUSIONS: Adavosertib showed preliminary efficacy when combined with chemotherapy. The most promising treatment combination was adavosertib 225 mg twice daily on days 1-3, 8-10, and 15-17 plus carboplatin every 21 days. However, hematologic toxicity was more frequent than would be expected for carboplatin monotherapy, and the combination requires further study to optimize the dose, schedule, and supportive medications.

Compound(41575-94-4)SDS of cas: 41575-94-4 received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150》. Authors are Hopkins, Ashley M.; Kichenadasse, Ganessan; McKinnon, Ross A.; Abuhelwa, Ahmad Y.; Logan, Jessica M.; Badaoui, Sarah; Karapetis, Christos S.; Rowland, Andrew; Sorich, Michael J..The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).COA of Formula: C6H12N2O4Pt. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

Abstract: Background: Proton pump inhibitors (PPIs) are commonly used concomitant to cancer treatment and they induce gut microbiota changes. It is increasingly apparent that gut dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). However, little is known about PPI effects on outcomes with ICIs, particularly in combination, ICI approaches. Methods: Post hoc, Cox proportional hazard anal. of phase III trial, IMpower150 was conducted to assess the association between PPI use and overall survival (OS) and progression-free survival (PFS) in chemotherapy-naive, metastatic non-squamous non-small cell lung cancer participants randomised atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP). PPI use was defined as any PPI administration between 30 days prior and 30 days after treatment initiation. Results: Of 1202 participants, 441 (37%) received a PPI. PPI use was independently associated with worse OS (n = 748; hazard ratio (HR) [95% confidence interval (CI)] = 1.53 [1.21-1.95], P < 0.001) and PFS (1.34 [1.12-1.61], P = 0.002) in the pooled atezolizumab arms (ACP plus ABCP). This association was not apparent for BCP (n = 368; OS 1.01 [0.73-1.39], P = 0.969; PFS 0.97 [0.76-1.25], P = 0.827). The observed OS treatment effect (HR 95% CI) of the atezolizumab (ACP plus ABCP) arms vs BCP was 1.03 (0.77-1.36) for PPI users compared to 0.68 (0.54-0.86) for non-users (P [interaction] = 0.028). A similar association was noted for ABCP vs BCP (PPI users 0.96 [0.68-1.35]; PPI non-users 0.66 [0.50-0.87]; P [interaction] = 0.095). Conclusions: PPI use was a neg. prognostic marker in patients treated with ACP or ABCP, but not BCP. The anal. suggests that PPIs neg. influence the magnitude of ICI efficacy. Compound(41575-94-4)COA of Formula: C6H12N2O4Pt received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.. Author is Swisher, Elizabeth M; Aghajanian, Carol; O’Malley, David M; Fleming, Gini F; Kaufmann, Scott H; Levine, Douglas A; Birrer, Michael J; Moore, Kathleen N; Spirtos, Nick M; Shahin, Mark S; Reid, Thomas J; Friedlander, Michael; Steffensen, Karina Dahl; Okamoto, Aikou; Sehgal, Vasudha; Ansell, Peter J; Dinh, Minh H; Bookman, Michael A; Coleman, Robert L.

OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with first-line chemotherapy and continued as maintenance for patients with ovarian carcinoma enrolled regardless of chemotherapy response or biomarker status. Here, we report exploratory analyses of the impact of homologous recombination deficient (HRD) or proficient (HRP) status on progression-free survival (PFS) and objective response rates during chemotherapy. METHODS: Women with Stage III-IV ovarian carcinoma were randomized to veliparib-throughout, veliparib-combination-only, or placebo. Stratification factors included timing of surgery and germline BRCA mutation status. HRD status was dichotomized at genomic instability score 33. During combination therapy, CA-125 levels were measured at baseline and each cycle; radiographic responses were assessed every 9 weeks. RESULTS: Of 1140 patients randomized, 742 had BRCA wild type (BRCAwt) tumors (HRP, n = 373; HRD/BRCAwt, n = 329). PFS hazard ratios between veliparib-throughout versus control were similar in both BRCAwt populations (HRD/BRCAwt: 22.9 vs 19.8 months; hazard ratio 0.76; 95% confidence interval [CI] 0.53-1.09; HRP: 15.0 vs 11.5 months; hazard ratio 0.765; 95% CI 0.56-1.04). By Cycle 3, the proportion with ≥90% CA-125 reduction from baseline was higher in those receiving veliparib (pooled arms) versus control (34% vs 23%; P = 0.0004); particularly in BRCAwt and HRP subgroups. Complete response rates among patients with measurable disease after surgery were 24% with veliparib (pooled arms) and 18% with control. CONCLUSIONS: These results potentially broaden opportunities for PARPi utilization among patients who would not qualify for frontline PARPi maintenance based on other trials.

Compound(41575-94-4)Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)(SMILESS: O=C1C2(CCC2)C(O[Pt]O1)=O.N.N,cas:41575-94-4) is researched.Category: benzofurans. The article 《Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience》 in relation to this compound, is published in Cancer Investigation. Let’s take a look at the latest research on this compound (cas:41575-94-4).

Large Cell Neuroendocrine Carcinoma of the Lung (L-LCNEC) is a rare type of neuroendocrine lung cancer that is increasingly diagnosed. However, the optimal management regarding the advanced stage is unclear. The purpose of this article is to present and compare our experience when L-LCNEC is treated as Small Cell Lung Cancer (SCLC). Overall, eight cases of L-LCNEC were included. We retrospectively reviewed medical files and reports by accessing the Institution’s Data of patients diagnosed with L-LCNEC from Apr. 2019 until Dec. 2020 and evaluated their response to the combination of Platinum – Etoposide – Atezolizumab as first-line chemotherapy. The overall observed response rate (ORR) of 75%. The median PFS was 6.85 mo. The median response duration was 5.5 mo. Comparing our findings with other retrospective and prospective studies, it seems that the systematic treatment of choice and management in L-LCNEC of the lung should be that of a small cell carcinoma of the lung.

When you point to this article, it is believed that you are also very interested in this compound(41575-94-4)COA of Formula: C6H12N2O4Pt and due to space limitations, I can only present the most important information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

COA of Formula: C6H12N2O4Pt. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about The fetal outcomes after neoadjuvant platinum and paclitaxel chemotherapy during pregnancy: analysis of three cases and review of the literature. Author is Wang, Ming; Yin, Ziran; Miao, Jinwei; Wu, Yumei.

Data on the outcomes of fetus who are exposed to neoadjuvant platinum and paclitaxel chemotherapy during pregnancy are lacking. Relevant data were abstracted from patients in our institution, PubMed, Embase and Cochrane Library databases. The primary assessment was the frequency of fetal death and congenital abnormalities. The secondary assessment was other neg. fetal/infant outcomes including FGR, RDS, secondary malignant diseases and other recorded adverse events. Of the three infants in our center who exposed to platinum and paclitaxel chemotherapy during pregnancy, the phys. evaluation and qualified Denver Developmental Screening Test showed normal findings at the last follow-up (19-24 mo). Hearing evaluation among three children also showed normal findings. Another 34 infants (including a twins) of 21 studies in previous studies who exposed to platinum and paclitaxel chemotherapy during pregnancy were included in the final anal. Of the 37 infants identified, 24 were exposed to cisplatin plus paclitaxel, and 13 were exposed to carboplatin plus paclitaxel. None of the 37 fetuses was abortion or dead during the pregnancy. 97.3% (36/37) infants were delivered by cesareans and the median gestational ages of delivery were 34.76 wk (95% CI, 34.08-35.44). 1 fetus showed intrauterine growth restriction and one was found with left-sided ventriculomegaly and hydramnios before chemotherapy. Adverse events occurred in 18.9% (7/37) infants at birth, including two RDS, one hearing loss, one pathol. jaundice, one first-degree intraventricular hemorrhage, one erythema, one corresponding to -0.5 standard deviation from average body weight of the same gestational weeks. No reports of neonatal cardiol. abnormalities are reported in these infants after the initiating of chemotherapy. The infant with congenital anomaly died 5 days after birth. During the follow-up, 5.4% (2/37) of the infants were diagnosed with malignant diseases. One retroperitoneal embryonal rhabdomyosarcoma at 5 years old and one acute myeloid leukemia at 22 mo of age. 32/37 (86.5%) children were healthy at the end of follow-ups (median 33 mo, IQR 15.75-54.25 mo). Our results showed that neoadjuvant platinum and paclitaxel combined chemotherapy was a feasible and safe choice for the management of patients with cervical and ovarian cancer during the second and third trimesters of gestation.

When you point to this article, it is believed that you are also very interested in this compound(41575-94-4)COA of Formula: C6H12N2O4Pt and due to space limitations, I can only present the most important information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)(SMILESS: O=C1C2(CCC2)C(O[Pt]O1)=O.N.N,cas:41575-94-4) is researched.Recommanded Product: 600-05-5. The article 《Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy》 in relation to this compound, is published in Cancer Science. Let’s take a look at the latest research on this compound (cas:41575-94-4).

The utility of Schlafen 11 (SLFN11) expression as a predictive biomarker for platinum-based chemotherapy has been established for cancers from different histologies. However, the therapeutic relevance of SLFN11 in bladder cancer (BC) is unknown. Here, we examined the clinicopathol. significance of SLFN11 expression across 120 BC cases by immunohistochem. We divided the cases into two cohorts, one including 50 patients who received adjuvant or neoadjuvant platinum-based chemotherapy, and the other including 70 BC patients treated by surgical resection without chemotherapy. In the cohort of 50 BC cases treated with platinum-based chemotherapy, the SLFN11-pos. group (n = 25) showed significantly better overall survival than the SLFN11-neg. group (n = 25, P = .012). Schlafen 11 expression correlated significantly with the expression of luminal subtype marker GATA3. Multivariate analyses identified SLFN11 expression as an independent prognostic predictor (odds ratio, 0.32; 95% confidence interval, 0.11-0.91; P = .033). Conversely, in the cohort of 70 BC cases not receiving platinum-based chemotherapy, the SLFN11-pos. group (n = 29) showed significantly worse overall survival than the SLFN11-neg. group (n = 41, P = .034). In vitro analyses using multiple BC cell lines confirmed that SLFN11 KO rendered cells resistant to cisplatin. The epigenetic modifying drugs 5-azacytidine and entinostat restored SLFN11 expression and resensitized cells to cisplatin and carboplatin in SLFN11-neg. BC cell lines. We conclude that SLFN11 is a predictive biomarker for BC patients who undergo platinum-based chemotherapy and that the combination of epigenetic modifiers could rescue refractory BC patients to platinum derivatives by reactivating SLFN11 expression.

When you point to this article, it is believed that you are also very interested in this compound(41575-94-4)Related Products of 41575-94-4 and due to space limitations, I can only present the most important information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics